Autres langues Johnson & Johnson

Actions

JNJ

US4781601046

Temps réel estimé Cboe BZX Autres places de cotation 20:01:19 29/04/2024			Varia. 5j.	Varia. 1 janv.
146,2 ^USD	+0,03 %		-1,98 %	-6,74 %

18:16	Bourse Zurich: le SMI s'approche des 11'400 points puis replonge dans le rouge	AW
16:34	J&J : avis positif du CHMP pour le cancer du poumon	CF

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

J&J : avis positif du CHMP pour le cancer du poumon	16:34
Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure	13:38
Johnson & Johnson Says Europe's CHMP Recommends Approval of Rybrevant Plus Chemotherapy for Lung Cancer Treatment	26/04
Johnson & Johnson : receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations	26/04
FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar	26/04
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset	24/04
Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study	24/04
Welfare Plan Class Action Litigation Underscores Importance Of Minding Your Fiduciary Duties	24/04
Johnson & Johnson to participate in the Bernstein's 40th Annual Strategic Decisions Conference	23/04
Janssen - CARVYKTI is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy	23/04
Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)	22/04
J&J : feu vert de l'UE pour Carvykti dans le myélome multiple	22/04
Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy	22/04
Contaminated cough syrup in Africa no longer available - WHO	22/04
WHO Likely to Issue Wider Warning About J&J Cough Syrup Contamination, Reuters Reports	19/04
La OMS ve "probable" una alerta más amplia por un jarabe para la tos de J&J contaminado	19/04
WHO says wider alert on contaminated J&J cough syrup 'likely'	19/04
US FDA mandates label updates on CAR-T cancer therapies	19/04
Medical device maker Intuitive beats estimates on strong demand for surgical robots	18/04
Johnson & Johnson : First Quarter 2024 2024 First-Quarter Earnings Transcript	18/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Joseph Wolk, CFO de J&J: Perte d'exclusivité de son médicament phare

Le 23 janvier 2024 à 18:30